Full Title
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in AdultsPurpose
Umbilical card blood is rich in healthy, blood-forming cells (stem cells) that are very good at fighting blood cancers. Cord blood transplants (CBT) are a standard treatment for adults with blood cancers who lack a genetically matched stem cell donor. Cord blood is donated by a baby’s mother at birth. CBT uses stem cells from cord blood collections to replace cells that have been destroyed by disease or anti-cancer treatment.
Memorial Sloan Kettering Cancer Center (MSK) has developed a standard (“optimized”) practice for CBT using FDA-approved drugs. This optimized practice includes standards for:
- How patients are assessed as candidates for transplant
- The conditioning treatment (standard chemotherapy and total body radiation therapy) used to prepare for transplant
- The amount of stem cells transplanted
- How people are followed during and after CBT
- How patients are monitored for complications after CBT
The purpose of this study is to see if MSK’s optimized CBT practice is safer and more effective. The people in this study have blood cancers with a high risk of returning after treatment, including:
- Acute myeloid leukemia
- Acute lymphoblastic leukemia
- Other acute leukemias
- Myelodysplastic syndromes
- Myeloproliferative disorders
- Non-Hodgkin lymphoma
- Blastic plasmacytoid dendritic cell neoplasm
Who Can Join
To join this study, there are a few conditions. You must:
- Have one of the blood cancers listed above, which has a high chance of coming back after treatment.
- Be recommended for a cord blood transplant.
- Have recovered from the serious side effect of previous therapies.
- Be age 21-65.
Contact
For more information about this study and to see if you can join, please call Dr. Ioannis Politikos’ office at 646-608-3773.